Just a few weeks before the US Food and Drug Administration would make the most controversial drug decision in years by approving Biogen, Inc.’s Aduhelm for Alzheimer’s – a decision many critics would argue was based more on the desire to give desperate patients hope than a true scientific advancement – newly appointed Center for Drug Evaluation and Research Director Patrizia Cavazzoni made a strong push to get emotion out of its advisory committee meetings.
“I think that we need to partner with industry on this, and I’m going to maybe say something that may not be welcomed by all, but I will speak it as a personal observation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?